Merck & Co denies flouting rules as litigation against HPV vaccines clouds Indian trials segment
This article was originally published in Scrip
Executive Summary
A public interest litigation (PIL) concerning the cervical cancer vaccines of Merck & Co (Gardasil) and GlaxoSmithKline (Cervarix) has added to a raft of negatives that have cast a shadow on India’s clinical trials segment, already under intense pressure and faced with a sharp deceleration in growth.